Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC022F in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT04626908Phase 2Unknown
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC022 in B-cell non-Hodgkin lymphoma. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 24 months. Status: unknown.
02
Drugs
GC022
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04626908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626908.